747
The current crisis which has ensued from the spreading of Covid-19 has upset the worldwide balance, seriously straining the entire healthcare system, with significant and inevitable consequences for many other sectors of the economy. Since the very beginning of the state of emergency, the institutions have tried to react by taking measures capable, on the one hand, of tackling the risk of the spread of the pandemic and, on the other, of remedying or avoiding severe repercussions such as, for example, the shortage of essential products, and also of ensuring that those products would be available at competitive prices. In this context, a central role is inevitably played by the pharmaceutical sector, it being the main addressee of the various emergency provisions and measures implemented, at national as well as at European level, to face the crisis.
